Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 14 February 2022

    ORYZON to give updates on corporate progress in February and March

  • 7 February 2022

    ORYZON reports results and corporate update for Q4 and year ended December 31, 2021

  • 11 January 2022

    ORYZON announces new Senior VP of Clinical Development and Global Medical Affairs, continuing its expansion of US corporate activities

  • 4 January 2022

    ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder

  • 3 January 2022

    ORYZON to hold multiple corporate activities in January

  • 13 December 2021

    ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

  • 22 November 2021

    ORYZON announces new Global Chief Business Officer and expansion of US corporate activities

  • 17 November 2021

    ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia

  • 15 November 2021

    ORYZON publishes paper in ACS Pharmacology & Translational Science supporting best-in-class performance of iadademstat in Oncology

  • 9 November 2021

    ORYZON to present new clinical data and corporate updates at international conferences in November and December

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy